Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

By Lahu Gezim   Hünnemeyer Andreas  

Clinical Pharmacokinetics, Vol. 49, Iss. 9, 2010-09 ,pp. : 589-606

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics of Nicotine and Its Metabolites I. Model Development

By Levi Micha   Dempsey Delia   Benowitz Neal   Sheiner Lewis  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 34, Iss. 1, 2007-02 ,pp. : 5-21

Springer Publishing Company

Access to resources Recommend Favorite

Validation of a population pharmacokinetic/pharmacodynamic model for 5 -reductase inhibitors

By Trouw R.A.J.   De Wit M.J.   Olsson Gisleskog P.   Hermann D.   Hammarlund-Udenaes M.   Karlsson M.O.  

European Journal of Pharmaceutical Sciences, Vol. 8, Iss. 4, 1999-08 ,pp. : 291-299

Elsevier

Access to resources Recommend Favorite

Population Pharmacokinetics of Digoxin in Japanese Patients: A 2-Compartment Pharmacokinetic Model

By Yukawa E.  

Clinical Pharmacokinetics, Vol. 40, Iss. 10, 2001-01 ,pp. : 773-781

Adis International

Access to resources Recommend Favorite

Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures: Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses

By Falcão Amilcar   Fuseau Eliane  

CNS Drugs, Vol. 26, Iss. 1, 2012-01 ,pp. : 79-91

Adis International

Access to resources Recommend Favorite